TICKERNERD
Menu
KODKODHealthcare · Biotechnology

KOD Stock Forecast: Kodiak Sciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$38
−3.79% on the day

The 6 Wall Street analysts covering Kodiak Sciences, Inc. hold a median 12-month price target of $66 — +72.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$2.4B
Ticker Nerd rank
47 / 100
Median analyst target
$66
Analysts covering
6
Total return, dividends reinvested
1W
−7.3%
1M
−9.6%
YTD
+37.1%
1Y
+294.7%
From 52W high
−17.5%
From 52W low
+348.3%
$9
$46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KOD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kodiak Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Accruals
88
Issuance
68
Value
67
Size
34
Revisions
29
Growth
27
Quality
25
Volatility
17

Momentum (96): The shares have been drifting up relative to others.

Volatility (17): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KOD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KOD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26KODHigh $85Median $66Low $56

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $56Median $66High $85

The green dot is the last close — the median target sits +72.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$58
3 Aug 2026JP MorganMaintainsOverweight—
3 Aug 2026JP MorganMaintainsOverweight$56 → $66
11 May 2026Chardan CapitalUpgradeBuy—
11 May 2026Chardan CapitalUpgradeBuy$14 → $61
27 Mar 2026HC Wainwright & Co.ReiteratesBuy—
27 Mar 2026UBSMaintainsBuy—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
22 Jan 2026HC Wainwright & Co.MaintainsBuy—
7 Jan 2026UBSInitiatesBuy—
17 Nov 2025Chardan CapitalMaintainsNeutral—
17 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025HC Wainwright & Co.UpgradeBuy—
24 Oct 2025JP MorganUpgradeOverweight—
23 Oct 2025LifeSci CapitalInitiatesOutperform—
6 Oct 2025Chardan CapitalMaintainsNeutral—
25 Sept 2025BarclaysUpgradeEqual-Weight—
22 Sept 2025JefferiesInitiatesBuy—
18 Aug 2025HC Wainwright & Co.MaintainsNeutral—
14 Aug 2025BarclaysMaintainsUnderweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KOD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KOD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Kodiak Sciences, Inc. (KOD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.9×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
39.4×

Cheaper than 3% of US stocks

EV / EBITDA
−10.1×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−368.4%

Higher than 4% of US stocks

Return on assets
−60.4%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KOD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KODKodiak Sciences, Inc.$2.4B
47
COAGHemab Therapeutics Holdings, Inc.$2.3B
2
URGNUroGen Pharma Ltd.$2.3B
82
VERAVera Therapeutics, Inc.$2.3B
26
MLYSMineralys Therapeutics, Inc.$2.3B
21
OCULOcular Therapeutix, Inc.$2.3B
32
RAPPRapport Therapeutics, Inc.$2.2B
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kodiak Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KOD news & analysis

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

Zacks Investment Research · 14 Aug 2026neutral

Kodiak Sciences reported a wider-than-expected Q2 loss while advancing its pipeline, with Zenkuda moving toward regulatory submission and key clinical data anticipated later in 2026.

Why it matters — KOD watchers would care because the progress of Zenkuda toward regulatory submission and upcoming clinical data are pivotal milestones for the company's pipeline and potential future value.

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

Zacks Investment Research · 11 Aug 2026positive

Kodiak Sciences has initiated a global Phase III study of KSI-501 for diabetic macular edema, testing the drug's dual mechanism targeting IL-6 and VEGF for more durable disease control.

Why it matters — This late-stage study marks a key regulatory milestone for Kodiak's pipeline, offering potential for a differentiated DME treatment if the dual-target approach proves successful.

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

PRNewsWire · 10 Aug 2026positive

Kodiak Sciences announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema. The trial is designed to demonstrate superiority of KSI-501 versus aflibercept.

Why it matters — This marks a key clinical milestone for Kodiak's lead candidate KSI-501, advancing toward a pivotal readout in the diabetic macular edema indication.

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

PRNewsWire · 6 Aug 2026positive

Kodiak Sciences announced completion of enrollment in the first 300-patient pivotal cohort of the Phase 3 PEAK trial for KSI-101, a treatment for macular edema secondary to inflammation. Topline clinical data from the 24-week primary endpoint remain on track for release in December 2026, with enrollment in the second pivotal cohort (600 subjects across PEAK and PINNACLE) expected by 4Q 2026.

Why it matters — This milestone advances the KSI-101 Phase 3 program and confirms the previously stated timeline for key clinical data, offering KOD watchers a concrete step toward the trial's next major catalysts in December 2026 and 2Q 2027.

FAQ

Frequently asked questions about KOD stock

What is the KOD stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Kodiak Sciences, Inc. have a median 12-month price target of $66, with estimates ranging from $56 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KOD stock a buy right now?

Of the 6 analysts covering Kodiak Sciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kodiak Sciences, Inc. 47 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KOD?

As at 22 Aug 2026, Kodiak Sciences, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will KOD stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +72.2% from the last close, and Ticker Nerd's factor model ranks Kodiak Sciences, Inc. 47 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KOD stock forecast for 2030?

No analyst covering Kodiak Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KOD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $56 to $85 over the next 12 months.

How has KOD stock performed over the past year?

Kodiak Sciences, Inc. returned +294.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kodiak Sciences, Inc. do?

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for retinal diseases.

What is the latest news on KOD?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus". Kodiak Sciences reported a wider-than-expected Q2 loss while advancing its pipeline, with Zenkuda moving toward regulatory submission and key clinical data anticipated later in 2026.

Company

About Kodiak Sciences, Inc.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for retinal diseases. The company specializes in next-generation therapies targeting chronic, high-prevalence ophthalmic conditions that lead to vision loss, including wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, uveitis, and macular edema secondary to inflammation. Its proprietary Antibody Biopolymer Conjugate Drug platform enables multi-modal treatments through bio-inspired antibody biopolymer conjugates. Key pipeline candidates include tarcocimab tedromer (KSI-301), an anti-VEGF antibody biopolymer in Phase 3 studies for retinal vascular diseases; KSI-501, a bispecific anti-IL-6 and VEGF-trap for inflammatory retinal conditions; and KSI-101, targeting IL-6 and VEGF for patients with retinal fluid and inflammation. Kodiak Sciences Inc. operates as a retina-focused biotechnology firm advancing late-stage programs to address unmet needs in ophthalmology. Founded in 2009 and headquartered in Palo Alto, California, it remains committed to developing innovative biologic medicines for complex ocular diseases.

CEO Dr. Victor Perlroth M.D. · 141 employees · United States · https://kodiak.com